Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
“Inavolisib is a potent (low picomolar Ki) inhibitor of the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) catalytic subunit alpha isoform protein (p110α; encoded by the PIK3CA gene). In addition, inavolisib promotes the degradation of mutated p110α (mutant degrader).”
“In clinical studies, the geometric mean of the individual elimination half-life estimate for inavolisib was 16.4 hours following a single 9 mg dose.”
Working under the parallel aged-care framework? Aged-care equivalent →
“Inavolisib is not a substrate for CYP450 enzymes, suggesting a low likelihood of interaction between inavolisib and CYP inhibitors or inducers.”